Co-Diagnostics' Joint Venture CoSara Diagnostics Completes Clinical Study and Regulatory Submission for Point-of-Care Tuberculosis Test, Sets Stage for Commercial Launch in India
CDSCO Clearance and Commercial Launch in India Anticipated Before Year-End 2026 Study Demonstrated 97.3% Sensitivity and 96.0% Specificity Consistent Performance Across Three Test Batches Integrated Mobile and Cloud Infrastructure Already Deployed in India to Support Anticipated...
Read the full story on PR Newswire → Opens the original article on www.prnewswire.comSummary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.